## Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
	Name
Name	
ID Number	Specialty
D.O.B. /_/ MM/DD/YYYY	Address
Diagnosis	City /State/Zip
Drug Name Entyvio	Phone: Fax:
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.
TEP 1: DISEASE STATE INFORMATION	
☐ Yes ☐ No If No, a prior authorization is not required for FEP members tha	t will be serviced by a provider within the health plan's geographic service area, please contact the health plan for questions regarding
☐ If primary, continue with questionset.	igh this process. Please contact the member's primary coverage for
receive this medication in a hospital outpatient se	

	eria Questions: Does the patient have a diagnosis of ulcerative colitis (UC) or Crol	nn's disease (CD)? □Yes* □No
	*If YES, please specify which:	
	Crohn's Disease (CD)	
_	Ulcerative Colitis (UC)	
	as the patient been on Entyvio continuously for the last 6 months	
	<b>INO</b> – this is <b>INITIATION</b> of therapy, please answer the follow a. Is the patient's condition moderate to severely active? □Yes	s •No
	b. Does the patient have an intolerance or contraindication or h conventional therapy? □Yes □No	ave they had an inadequate treatment response to at least one
	c. Does the prescriber agree to re-evaluate the patient's condition continued? \(\sigma\)Yes \(\sigma\)No	on at week 14 to confirm therapy with Entyvio should be
	d. Does the prescriber agree to initiate dosing via IV infusion o	n weeks 0 and 2? □Yes □No
	e. Does the prescriber agree to administer the medication within every 8 weeks? □Yes □No	n the FDA labeled maintenance dose of 300mg intravenously
1	☐ YES – this is a PA renewal for CONTINUATION of therapy,	please answer the following question:
	a. Does the prescriber agree to administer the medication within every 8 weeks? □Yes □No	n the FDA labeled maintenance dose of 300mg intravenously
	Vill this medication be given in combination with any other biologard <i>YES</i> , please specify the medication:	gic DMARD or targeted synthetic DMARD? □Yes* □No
otes are	e required for the processing of all requests. Please add any other support Coverage will not be provided if the prescribing physician's sign	
est for expe	dited review: I certify that applying the standard review time frame may seriously jeopardize the life or healt	
ian's Nai	me Physician Signature	Date
: list	☐ Form Completely Filled Out	☐ Attach test results
	Provide chart notes	By Mail: BCBSM Specialty Pharmacy Program
:	By Fax: BCBSM Specialty Pharmacy Mailbox	Ry Mall, RC RNM Subclaim huarmach hrousam

1-877-325-5979

Submit

P.O. Box 312320, Detroit, MI 48231-2320